Fager G - Search Results

1

Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects.

Sarich TC, Wolzt M, Eriksson UG, Mattsson C, Schmidt A, Elg S, Andersson M, Wollbratt M, Fager G, Gustafsson D. Sarich TC, et al. Among authors: fager g. J Am Coll Cardiol. 2003 Feb 19;41(4):557-64. doi: 10.1016/s0735-1097(02)02868-1. J Am Coll Cardiol. 2003. PMID: 12598065 Free article. Clinical Trial.

2

Acute antithrombotic effects of ximelagatran, an oral direct thrombin inhibitor, and r-hirudin in a human ex vivo model of arterial thrombosis.

Sarich TC, Osende JI, Eriksson UG, Fager GB, Eriksson-Lepkowska M, Ohlsson L, Carlsson S, Wåhlander K, Gustafsson D, Badimon JJ. Sarich TC, et al. Among authors: fager gb. J Thromb Haemost. 2003 May;1(5):999-1004. doi: 10.1046/j.1538-7836.2003.00201.x. J Thromb Haemost. 2003. PMID: 12871368 Free article. Clinical Trial.

3

Inhibition of thrombin generation by the oral direct thrombin inhibitor ximelagatran in shed blood from healthy male subjects.

Sarich TC, Eriksson UG, Mattsson C, Wolzt M, Frison L, Fager G, Gustafsson D. Sarich TC, et al. Among authors: fager g. Thromb Haemost. 2002 Feb;87(2):300-5. Thromb Haemost. 2002. PMID: 11858491 Clinical Trial.

4

Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans.

Eriksson UG, Bredberg U, Hoffmann KJ, Thuresson A, Gabrielsson M, Ericsson H, Ahnoff M, Gislén K, Fager G, Gustafsson D. Eriksson UG, et al. Among authors: fager g. Drug Metab Dispos. 2003 Mar;31(3):294-305. doi: 10.1124/dmd.31.3.294. Drug Metab Dispos. 2003. PMID: 12584156

5

Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.

Johansson LC, Frison L, Logren U, Fager G, Gustafsson D, Eriksson UG. Johansson LC, et al. Among authors: fager g. Clin Pharmacokinet. 2003;42(4):381-92. doi: 10.2165/00003088-200342040-00006. Clin Pharmacokinet. 2003. PMID: 12648028 Clinical Trial.

6

No influence of ethnic origin on the pharmacokinetics and pharmacodynamics of melagatran following oral administration of ximelagatran, a novel oral direct thrombin inhibitor, to healthy male volunteers.

Johansson LC, Andersson M, Fager G, Gustafsson D, Eriksson UG. Johansson LC, et al. Among authors: fager g. Clin Pharmacokinet. 2003;42(5):475-84. doi: 10.2165/00003088-200342050-00005. Clin Pharmacokinet. 2003. PMID: 12739985 Clinical Trial.

7

Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid.

Fager G, Cullberg M, Eriksson-Lepkowska M, Frison L, Eriksson UG. Fager G, et al. Eur J Clin Pharmacol. 2003 Aug;59(4):283-9. doi: 10.1007/s00228-003-0619-x. Epub 2003 Jul 4. Eur J Clin Pharmacol. 2003. PMID: 12845508 Clinical Trial.

8

Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran.

Eriksson UG, Johansson S, Attman PO, Mulec H, Frison L, Fager G, Samuelsson O. Eriksson UG, et al. Among authors: fager g. Clin Pharmacokinet. 2003;42(8):743-53. doi: 10.2165/00003088-200342080-00003. Clin Pharmacokinet. 2003. PMID: 12846595 Clinical Trial.

9

No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.

Wåhlander K, Eriksson-Lepkowska M, Frison L, Fager G, Eriksson UG. Wåhlander K, et al. Among authors: fager g. Clin Pharmacokinet. 2003;42(8):755-64. doi: 10.2165/00003088-200342080-00004. Clin Pharmacokinet. 2003. PMID: 12846596 Clinical Trial.

10

A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery.

Eriksson BI, Arfwidsson AC, Frison L, Eriksson UG, Bylock A, Kälebo P, Fager G, Gustafsson D. Eriksson BI, et al. Among authors: fager g. Thromb Haemost. 2002 Feb;87(2):231-7. Thromb Haemost. 2002. PMID: 11858482 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

63 results

Search Page

Filters